Sony Group is set to announce its third-quarter results on Wednesday. Here are the key details:
Net Profit Forecast
According to a poll of analysts by Visible Alpha, Sony Group is expected to see a 2.3% decline in net profit, amounting to 319.23 billion yen ($2.14 billion) for the three months ended Dec. 31. This compares with a net profit of Y326.81 billion in the same period last year.
Revenue Forecast
The Visible Alpha poll also estimates that third-quarter revenue will increase by 5.6% from the previous year, reaching Y3.603 trillion.
Stock Performance
As of Friday, Sony Group's stock has risen by 6.2% in 2024, following a gain of 9.6% in the October-December period. The stock closed at Y14,235 on Friday. Japanese markets were closed on Monday due to a public holiday.
What to Watch For
- Second-quarter operating profit from Sony Group's game business saw a 16% increase compared to the previous year, amounting to Y48.90 billion. Investors are eagerly awaiting further profit growth in this key segment, especially during the holiday shopping season.
- Sony Group has projected a 13% rise in revenue to Y12.400 trillion for the fiscal year ending in March, with a 12% decrease in net profit to Y880.00 billion. Investors will be paying close attention to any updates or adjustments to this guidance.
- Second-quarter operating profit from Sony Group's imaging and sensing business experienced a 37% decrease compared to the previous year, reaching Y46.36 billion. This decline was partly due to costs related to the mass production of new image sensors for mobile devices. Investors are hoping for signs of recovery in this segment as the global smartphone market starts to rebound.
Related Articles
Burgers vs. Burritos: A Tale of Two Stocks
McDonald's shares rise as Chipotle's plummet, but Chipotle's long-term growth potential and valuation make it worth considering.
Country Garden Holdings Reports First-Half Results
Country Garden Holdings will release its first-half financial results, expecting a net loss. The company focuses on debt management, cash position, and cost red...
Grifols Sells 20% Stake in Chinese Medicine Developer
Barcelona-based pharmaceutical company, Grifols, plans to sell a 20% stake in Shanghai RAAS Blood Products to reduce debt, leading to a surge in shares.